The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

The most common subtype of renal cell carcinoma is clear cell renal cell carcinoma
(ccRCC). While localized ccRCC can be cured with surgery, metastatic disease has a poor …

Standard treatment for localized non-metastatic renal cell carcinoma (RCC) is radical or
partial nephrectomy. However, after radical surgery, patients with stage II-III have a …

The clinical presentation of renal cell cancer (RCC) is shifting towards incidental and early
detection, creating new challenges in RCC diagnosis. Overtreatment might be reduced with …

The 2020s utilize the molecular profiling of advanced RCC as a scaffold for recent trials in
immunotherapy and targeted therapies. Going forward, emphasizing patient-reported …

Background Renal c carcinoma (RCC) is one of the most common urinary cancers
worldwide, with a predicted increase in incidence in the coming years. Immunotherapy, as a …

Antibody–drug conjugates (ADCs) are complex chemical structures composed of a
monoclonal antibody, serving as a link to target cells, which is conjugated with a potent …

Background The role of cytoreductive nephrectomy (CN) has not yet been well characterized
in the era of combination immunotherapy. Objective To evaluate characteristics and …

Background There are limited data evaluating the activity of cabozantinib (CABO) as second
line (2L) therapy post standard of care ipilimumab-nivolumab (IPI-NIVO) or immuno …

Simple Summary Tyrosine kinase inhibitors and immune checkpoint inhibitors have
substantially prolonged survival in patients affected by advanced renal cell carcinoma …